With the emergence of oral cancer therapies, it is a very exciting time in cancer care. But these treatments can come with adverse events. Dr. Pavani Chalasani from the University of Arizona Cancer Center shares how she educates patients on what to expect from oral cancer therapies and her focus on one of the most underestimated symptoms for patients.

Pavani Chalasani, MD, MPH

Associate Professor of Medicine

University of Arizona Cancer Center

Tucson, AZ

Related Content:

• Addressing Challenges in Oral Therapies for HR+, HER2- Breast Cancer
• Targeted Drug Therapy | Breast Cancer Treatment (American Cancer Society)
• Hormone Therapy for Breast Cancer | Breast Cancer Treatment (American Cancer Society)
• 2018 Hematology/Oncology Pharmacist Association Best Practices for the Management of Oral Oncolytic Therapy: Pharmacy Practice Standard
• Challenges of Caregivers of Cancer Patients who are on Oral Oncolytic Therapy
• Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

This is the first video podcast in a series from the “Addressing Challenges in Oral Therapies for HR+, HER2- Breast Cancer” education program.

Funding and support provided by Lilly Oncology. VV-OTHR-US-DEL-0876 © Lilly USA, LLC 2022. All rights reserved.

©2022. Association of Community Cancer Centers. All rights reserved. No part of this production may be reproduced or transmitted in any form or by any means without written permission.